Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis

  Free Subscription


Articles published in J Viral Hepat

Retrieve available abstracts of 297 articles:
HTML format
Text format



Single Articles


    December 2018
  1. POURMARZI D, Hall L, Hepworth J, Smirnov A, et al
    Clinical effectiveness, cost effectiveness and acceptability of community-based treatment of Hepatitis C Virus infection: a mixed method systematic review.
    J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13045.
    PubMed     Text format     Abstract available


  2. LEE SS, Kim CY, Kim BR, Cha RR, et al
    Hepatitis C virus genotype 3 was associated with the development of hepatocellular carcinoma in Korea.
    J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13047.
    PubMed     Text format     Abstract available


  3. RAUWOLF K, Herbruggen H, Zollner S, Thorer H, et al
    Durable control of Hepatitis C through interferon-free antiviral combination therapy immediately prior to allogeneic hematopoietic stem cell transplantation.
    J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13046.
    PubMed     Text format     Abstract available


    November 2018
  4. HOLMES JA, Carlton-Smith C, Kim AY, Dumas EO, et al
    Dynamic Changes in Innate Immune Responses During Direct Acting Antiviral Therapy for HCV Infection.
    J Viral Hepat. 2018 Nov 19. doi: 10.1111/jvh.13041.
    PubMed     Text format     Abstract available


  5. MIJOCEVIC H, Karimzadeh H, Seebach J, Usman Z, et al
    Variants of hepatitis B virus surface antigen observed during therapy with nucleic acid polymer REP 2139-Ca have no influence on treatment outcome and its detection by diagnostic assays.
    J Viral Hepat. 2018 Nov 19. doi: 10.1111/jvh.13044.
    PubMed     Text format     Abstract available


  6. KAPILA N, Flocco G, Al Khalloufi K, Zervos XB, et al
    Transplantation of kidneys from HCV viremic donors to HCV viremic recipients followed by early direct acting anti-viral therapy without ribavirin.
    J Viral Hepat. 2018 Nov 18. doi: 10.1111/jvh.13042.
    PubMed     Text format     Abstract available


  7. BUTT ZA, Mak S, Gesink D, Gilbert M, et al
    Applying core theory and spatial analysis to identify Hepatitis C Virus infection 'core areas' in British Columbia, Canada.
    J Viral Hepat. 2018 Nov 17. doi: 10.1111/jvh.13043.
    PubMed     Text format     Abstract available


  8. SCHULKIND J, Stephens B, Ahmad F, Johnston L, et al
    High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme.
    J Viral Hepat. 2018 Nov 13. doi: 10.1111/jvh.13035.
    PubMed     Text format     Abstract available


  9. FLAMM S, Mutimer D, Asatryan A, Wang S, et al
    Glecaprevir/Pibrentasvir in Patients with Chronic HCV Genotype 3 Infection: An Integrated Phase 2/3 Analysis.
    J Viral Hepat. 2018 Nov 12. doi: 10.1111/jvh.13038.
    PubMed     Text format     Abstract available


  10. GILL US, Kennedy PTF
    The impact of currently licensed therapies on viral and immune responses in Chronic Hepatitis B: considerations for future novel therapeutics.
    J Viral Hepat. 2018 Nov 11. doi: 10.1111/jvh.13040.
    PubMed     Text format     Abstract available


  11. SONG J, Yang F, Wang S, Tikande S, et al
    Efficacy and safety of antiviral treatment on blocking the mother-to-child transmission of hepatitis B virus: a meta-analysis.
    J Viral Hepat. 2018 Nov 11. doi: 10.1111/jvh.13036.
    PubMed     Text format     Abstract available


  12. SERFATY L, Jacobson I, Rockstroh J, Altice FL, et al
    The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: an integrated analysis.
    J Viral Hepat. 2018 Nov 9. doi: 10.1111/jvh.13037.
    PubMed     Text format     Abstract available


  13. YOUNG K, Liu B, Bhuket T, Gish RG, et al
    Improved Liver Transplant Waitlist Mortality and Lower Risk of Disease Progression Among Chronic Hepatitis C Patients Awaiting Liver Transplantation After the Introduction of Direct Acting Antiviral Therapies in the United States.
    J Viral Hepat. 2018 Nov 9. doi: 10.1111/jvh.13039.
    PubMed     Text format     Abstract available


  14. ORR C, Aartun J, Masur H, Kottilil S, et al
    Characterization of Changes in Intrahepatic Immune Cell Populations During HCV Treatment with Sofosbuvir and Ribavirin.
    J Viral Hepat. 2018 Nov 1. doi: 10.1111/jvh.13034.
    PubMed     Text format     Abstract available


  15. YOUNOSSI Z, Papatheodoridis G, Cacoub P, Negro F, et al
    The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease.
    J Viral Hepat. 2018;25 Suppl 3:6-14.
    PubMed     Text format     Abstract available


    October 2018
  16. BRICHLER S, Nahon P, Zoulim F, Layese R, et al
    Non-virological factors are drivers of Hepatocellular Carcinoma in virosuppressed Hepatitis B cirrhosis: results of ANRS CO12 CirVir cohort.
    J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13029.
    PubMed     Text format     Abstract available


  17. DONG XQ, Wu Z, Zhao H, Wang GQ, et al
    Evaluation and Comparison of Thirty Non-invasive Models for Diagnosing Liver Fibrosis in Chinese Hepatitis B Patients.
    J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13031.
    PubMed     Text format     Abstract available


  18. WU DB, Jiang W, Wang YH, Chen B, et al
    Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in southwest China: real-world experience of a retrospective study.
    J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13033.
    PubMed     Text format     Abstract available


  19. WU Z, Dong X, Wang G, Zhao H, et al
    Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal.
    J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13030.
    PubMed     Text format     Abstract available


  20. ABDEL GHAFFAR TY, Naghi SE, Gawad MA, Helmy S, et al
    Safety and Efficacy of Combined Sofosbuvir/Daclatasvir Treatment of Children and Adolescents with Chronic Hepatitis C Genotype 4.
    J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13032.
    PubMed     Text format     Abstract available


  21. HUANG J, Yin P, Zhang L
    COPII cargo claudin-12 promotes hepatitis C virus entry.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13026.
    PubMed     Text format     Abstract available


  22. SARKAR M, Lai JC, Sawinski D, Zeigler TE, et al
    Sex Hormone Levels by Presence and Severity of Cirrhosis in Women With Chronic Hepatitis C Virus (HCV) Infection.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13027.
    PubMed     Text format     Abstract available


  23. CHEVALIEZ S, Rodriguez C, Poiteau L, Soulier A, et al
    Primary Resistance of Hepatitis B Virus to Nucleoside and Nucleotide Analogues.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13025.
    PubMed     Text format     Abstract available


  24. WANG M, Ping Y, Li Z, Li J, et al
    Polarization of granulocytic myeloid-derived suppressor cells by hepatitis C core protein is mediated via IL-10/STAT3 signaling.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13024.
    PubMed     Text format     Abstract available


  25. VAZIRI A, Gimson A, Agarwal K, Aldersley M, et al
    Liver transplant listing for hepatitis C associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct acting antiviral therapy.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13022.
    PubMed     Text format     Abstract available


  26. GIRARDIN F, Hearmon N, Negro F, Eddowes L, et al
    Increasing Hepatitis C Virus Screening in People Who Inject Drugs in Switzerland Using Rapid Antibody Saliva and Dried Blood Spot Testing: a Cost-Effectiveness Analysis.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13023.
    PubMed     Text format     Abstract available


  27. KNOP V, Hofmann WP, Buggisch P, Klinker H, et al
    Estimation of liver fibrosis by non-commercial serum markers in comparison to transient elastography in patients with chronic hepatitis C virus infection receiving direct acting antiviral treatment.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13021.
    PubMed     Text format     Abstract available


  28. MOREY S, Hamoodi A, Jones D, Young T, et al
    Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13017.
    PubMed     Text format     Abstract available


  29. GOUTZAMANIS S, Doyle J, Higgs P, Hellard M, et al
    Improving hepatitis C direct-acting antiviral access and uptake: a role for patient-reported outcomes and lived-experience.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13020.
    PubMed     Text format     Abstract available


  30. ASGARI S, Chaturvedi N, Scepanovic P, Hammer C, et al
    Human genomics of acute liver failure due to hepatitis B virus infection: an exome sequencing study in liver transplant recipients.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13019.
    PubMed     Text format     Abstract available


  31. MCLEOD A, Weir A, Hutchinson SJ, Goldberg DJ, et al
    Hepatitis C test uptake among historic blood transfusion recipients following media coverage of the Penrose Inquiry and an awareness-raising campaign.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13016.
    PubMed     Text format     Abstract available


  32. JAYASUNDARA D, Hui BB, Regan DG, Heywood AE, et al
    Modelling the decline and future of hepatitis A transmission in Australia.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13018.
    PubMed     Text format     Abstract available


    September 2018
  33. OU G, Liu X, Yang L, Yu H, et al
    Relationship between HLA-DPA1 mRNA expression and susceptibility to hepatitis B.
    J Viral Hepat. 2018 Sep 29. doi: 10.1111/jvh.13012.
    PubMed     Text format     Abstract available


  34. JOO EJ, Chang Y, Yeom JS, Cho YK, et al
    Chronic Hepatitis B Virus Infection and Risk of Dyslipidemia: A Cohort Study.
    J Viral Hepat. 2018 Sep 29. doi: 10.1111/jvh.13014.
    PubMed     Text format     Abstract available


  35. KWON JA, Dore GJ, Grebely J, Hajarizadeh B, et al
    Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: a modeling study.
    J Viral Hepat. 2018 Sep 29. doi: 10.1111/jvh.13013.
    PubMed     Text format     Abstract available


  36. HERNANDEZ-CONDE M, Fernandez I, Perello C, Gallego A, et al
    Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: results from the Spanish HEPA-C real-world cohort.
    J Viral Hepat. 2018 Sep 28. doi: 10.1111/jvh.13008.
    PubMed     Text format     Abstract available


  37. MALAGUTI A, Sani F, Stephens BP, Ahmad F, et al
    Change in injecting behaviour among people treated for hepatitis C virus: the role of intimate partnerships.
    J Viral Hepat. 2018 Sep 27. doi: 10.1111/jvh.13009.
    PubMed     Text format     Abstract available


  38. XIA Y, Pan W, Ke X, Skibbe K, et al
    Differential escape of HCV from CD8(+) T cell selection pressure between China and Germany depends on the presenting HLA class I molecule.
    J Viral Hepat. 2018 Sep 27. doi: 10.1111/jvh.13011.
    PubMed     Text format     Abstract available


  39. MIAO Z, Zhang S, Ma Z, Hakim MS, et al
    Recombinant identification, molecular classification and proposed reference genomes for hepatitis delta virus.
    J Viral Hepat. 2018 Sep 27. doi: 10.1111/jvh.13010.
    PubMed     Text format     Abstract available


  40. LIU Z, Chen X, Zhang T
    Reply to "The epidemiology of hepatitis B virus infection in China".
    J Viral Hepat. 2018 Sep 21. doi: 10.1111/jvh.13007.
    PubMed     Text format     Abstract available


  41. MACIAS J, Tellez F, Rivero-Juarez A, Palacios R, et al
    Early emergence of opportunistic infections after starting direct acting antiviral drugs in HIV/HCV coinfected patients.
    J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13003.
    PubMed     Text format     Abstract available


  42. LIN SYC, Magalis BR, Salemi M, Liu HF, et al
    Origin and Dissemination of Hepatitis B Virus Genotype C in East Asia Revealed by Phylodynamic Analysis and Historical Correlates.
    J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13006.
    PubMed     Text format     Abstract available


  43. ZHAO H
    The epidemiology of hepatitis B virus infection in China.
    J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13004.
    PubMed     Text format     Abstract available


  44. IWAMOTO M, Calzia A, Dublineau A, Rouet F, et al
    Field evaluation of GeneXpert((R)) (Cepheid) HCV performance for RNA quantification in a Genotype 1 and 6 predominant patient population in Cambodia.
    J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13002.
    PubMed     Text format     Abstract available


  45. BIANCHI FP, Gallone MS, Gallone MF, Larocca AMV, et al
    HBV seroprevalence after 25 years of universal mass vaccination and management of non-responders to the anti-Hepatitis B vaccine: an Italian study among medical students.
    J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13001.
    PubMed     Text format     Abstract available


  46. RODGERS MA, Holzmayer V, Vallari A, Olivo A, et al
    Hepatitis C virus surveillance and identification of human pegivirus 2 in a large Cameroonian cohort.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12996.
    PubMed     Text format     Abstract available


  47. DUONG MC, McLaws ML
    Screening hemodialysis patients for hepatitis C in Vietnam: the inconsistency between common hepatitis C virus serological and virological tests.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12994.
    PubMed     Text format     Abstract available


  48. VAN CAMPENHOUT MJH, Brouwer WP, Xie Q, Guo S, et al
    Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg positive chronic hepatitis B infection: ARES long-term follow-up.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12997.
    PubMed     Text format     Abstract available


  49. SUKRITI S, Choudhary MC, Maras JS, Sharma S, et al
    Extracellular Vesicles From Hepatitis B Patients Serve As Reservoir Of Hepatitis B Virus DNA.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12995.
    PubMed     Text format     Abstract available


  50. VROLING H, Oordt-Speets AM, Madeddu G, Babudieri S, et al
    A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12998.
    PubMed     Text format     Abstract available


  51. CHAN HLY, Chan FWS, Hui AJ, Li MKK, et al
    Switching to Peginterferon for Chronic Hepatitis B Patients with Hepatitis B e Antigen Seroconversion on Entecavir - A Prospective Study.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.13000.
    PubMed     Text format     Abstract available


  52. HONER ZU SIEDERDISSEN C, Maasoumy B, Cornberg M
    New viral biomarkers for Hepatitis B: Are we able to change practice?
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12993.
    PubMed     Text format     Abstract available


  53. LAMPERTICO P, Brunetto MR, Craxi A, Gaeta GB, et al
    Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12999.
    PubMed     Text format     Abstract available


  54. SHEN J, Liu J, Li C, Wen T, et al
    The prognostic significance of serum HBeAg on the recurrence and long-term survival after hepatectomy for hepatocellular carcinoma: A propensity score matching analysis.
    J Viral Hepat. 2018;25:1057-1065.
    PubMed     Text format     Abstract available


  55. WANG J, Yu Y, Li G, Shen C, et al
    Natural history of serum HBV-RNA in chronic HBV infection.
    J Viral Hepat. 2018;25:1038-1047.
    PubMed     Text format     Abstract available


    August 2018
  56. LAFFERTY L, Rance J, Grebely J, Lloyd AR, et al
    Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12987.
    PubMed     Text format     Abstract available


  57. PERPINAN E, Caro-Perez N, Garcia-Gonzalez N, Gregori J, et al
    Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12986.
    PubMed     Text format     Abstract available


  58. SAEED S, Moodie EE, Strumpf E, Gill J, et al
    Real-World Impact of Direct Acting Antiviral Therapy on Health-Related Quality of Life in HIV/Hepatitis C Co-Infected Individuals.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12985.
    PubMed     Text format     Abstract available


  59. JONES H, Patel P, Sears D
    Electronic Reminders Increase Hepatitis C Screening, referral, treatment and cure.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12988.
    PubMed     Text format     Abstract available


  60. MACIAS J, Granados R, Tellez F, Merino D, et al
    Similar recovery of liver function after response to all oral HCV therapy in patients with cirrhosis with and without HIV coinfection.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12990.
    PubMed     Text format     Abstract available


  61. LIM SG, Phyo WW, Shah SR, Win KM, et al
    Findings from a large asian chronic hepatitis c real life study.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12989.
    PubMed     Text format     Abstract available


  62. GROC S, Abbate JL, Le Gal F, Gerber A, et al
    High Prevalence and Diversity of Hepatitis B and Hepatitis Delta Virus in Gabon.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12991.
    PubMed     Text format     Abstract available


  63. DIRKS M, Haag K, Pflugrad H, Tryc AB, et al
    Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients.
    J Viral Hepat. 2018 Aug 18. doi: 10.1111/jvh.12979.
    PubMed     Text format     Abstract available


  64. SINGH A, Kumari S, Kumar P, De A, et al
    Sofosbuvir with NS5A Inhibitors in Hepatitis C Virus (HCV) Infection with Severe Renal Insufficiency.
    J Viral Hepat. 2018 Aug 16. doi: 10.1111/jvh.12983.
    PubMed     Text format     Abstract available


  65. ARYA RP, Mishra N, Biswas K, Arankalle VA, et al
    Association of Toll-like receptor 4 polymorphism with Hepatitis E virus infected Indian patients.
    J Viral Hepat. 2018 Aug 16. doi: 10.1111/jvh.12980.
    PubMed     Text format     Abstract available


  66. MASETTI C, Lionetti R, Lupo M, Siciliano M, et al
    Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hcv-related cirrhosis.
    J Viral Hepat. 2018 Aug 16. doi: 10.1111/jvh.12982.
    PubMed     Text format     Abstract available


  67. WANG S, Wang J, Fan MJ, Li TY, et al
    Identified OAS3 gene variants associated with coexistence of HBsAg and anti-HBs in chronic HBV infection.
    J Viral Hepat. 2018;25:904-910.
    PubMed     Text format     Abstract available


  68. CHOI YH, Zhang X, Tran C, Skinner B, et al
    Expression profiles of host immune response-related genes against HEV genotype 3 and genotype 1 infections in rhesus macaques.
    J Viral Hepat. 2018;25:986-995.
    PubMed     Text format     Abstract available


  69. WANG B, Carey I, Bruce M, Montague S, et al
    HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
    J Viral Hepat. 2018;25:886-893.
    PubMed     Text format     Abstract available


    July 2018
  70. SCOTT N, Sacks-Davis R, Pedrana A, Doyle J, et al
    Eliminating hepatitis C: the importance of frequent testing of people who inject drugs in high prevalence settings.
    J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12975.
    PubMed     Text format     Abstract available


  71. PINTILIE H, Brook G
    Commentary: A review of risk of hepatitis B and C transmission through biting or spitting.
    J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12976.
    PubMed     Text format     Abstract available


  72. DARVISHIAN M, Janjua NZ, Chong M, Cook D, et al
    Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk.
    J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12977.
    PubMed     Text format     Abstract available


  73. BILOUNGA NDONGO C, Eteki L, Siedner M, Mbaye R, et al
    Prevalence and vaccination coverage of Hepatitis B among healthcare workers in Cameroon: A national seroprevalence survey.
    J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12974.
    PubMed     Text format     Abstract available


  74. SUGIURA A, Joshita S, Umemura T, Yamazaki T, et al
    Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals.
    J Viral Hepat. 2018 Jul 25. doi: 10.1111/jvh.12973.
    PubMed     Text format     Abstract available


  75. WEI L, Chen D, Zhang B, Zhao Y, et al
    Long-term Outcome and Recurrence of Hepatitis B Virus following Liver Transplantation from Hepatitis B Surface Antigen-positive Donors in a Chinese Population.
    J Viral Hepat. 2018 Jul 15. doi: 10.1111/jvh.12972.
    PubMed     Text format     Abstract available


  76. KIM BG, Park NH, Lee SB, Lee H, et al
    Mortality, liver transplantation, and hepatic complications in patients with treatment-naive chronic hepatitis B treated with entecavir vs tenofovir.
    J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12971.
    PubMed     Text format     Abstract available


  77. NOMURA M, Tsuge M, Uchida T, Hiraga N, et al
    CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients.
    J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12970.
    PubMed     Text format     Abstract available


  78. KABERG M, Naver G, Hammarberg A, Weiland O, et al
    Incidence and spontaneous clearance of hepatitis C (HCV) in PWID at the Stockholm Needle Exchange - importance for HCV elimination.
    J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12969.
    PubMed     Text format     Abstract available


  79. HAYASHI K, Ishigami M, Ishizu Y, Kuzuya T, et al
    Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.
    J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12967.
    PubMed     Text format     Abstract available


  80. YUE X, Yang T, Zhao Y
    Response to letter to the editor: Is revaccination required in children who received a full primary vaccination against hepatitis B in infancy?!
    J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12968.
    PubMed     Text format     Abstract available


  81. YOUNOSSI ZM, Stepanova M, Henry L, Han KH, et al
    Sofosbuvir and Ledipasvir is Associated with High Sustained Virologic Response and Improvement of Health-Related Quality of Life in East Asian Patients with Hepatitis C Virus Infection.
    J Viral Hepat. 2018 Jul 4. doi: 10.1111/jvh.12965.
    PubMed     Text format     Abstract available


  82. MOHAMED Z, Rwegasha J, Kim JU, Shimakawa Y, et al
    The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania.
    J Viral Hepat. 2018 Jul 3. doi: 10.1111/jvh.12966.
    PubMed     Text format     Abstract available


  83. LIU Y, Song C, Ni H, Jiao W, et al
    UBE2L3, a susceptibility gene that plays oncogenic role in hepatitis B related hepatocellular carcinoma.
    J Viral Hepat. 2018 Jul 3. doi: 10.1111/jvh.12963.
    PubMed     Text format     Abstract available


  84. ANWAR N, Sherman KE
    Transplanting organs from hepatitis B positive donors: Is it safe? Is it ethical?
    J Viral Hepat. 2018 Jul 3. doi: 10.1111/jvh.12962.
    PubMed     Text format     Abstract available


  85. TAN J, Mao X, Zhang G, Wang W, et al
    Hepatitis B surface antigen positivity during pregnancy and risk of gestational diabetes mellitus: A systematic review and meta-analysis.
    J Viral Hepat. 2018 Jul 3. doi: 10.1111/jvh.12964.
    PubMed     Text format     Abstract available


    June 2018
  86. HSIEH YH, Patel AV, Loevinsohn GS, Thomas DL, et al
    Emergency Departments at the Crossroads of Intersecting Epidemics (HIV, HCV, Injection Drug Use, and Opioid Overdose) - Estimating HCV Incidence in an Urban Emergency Department Population.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12948.
    PubMed     Text format     Abstract available


  87. KUMAR R
    Hepatitis B Virus Infection and Diabetes Mellitus: An Adverse Relationship.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12949.
    PubMed     Text format     Abstract available


  88. ZHOU TC, Li X, Chen LJ, Fan JH, et al
    Differential expression profile of hepatic circular RNAs in chronic hepatitis B.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12944.
    PubMed     Text format     Abstract available


  89. LUTTERKORT GL, Wranke A, Hengst J, Yurdaydin C, et al
    Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12947.
    PubMed     Text format     Abstract available


  90. HARIDY J, Wigg A, Muller K, Ramachandran J, et al
    Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12943.
    PubMed     Text format     Abstract available


  91. DINESHA TR, Boobalan J, Sivamalar S, Subashini D, et al
    Occult HBV infection in HIV-infected adults and evaluation of pooled NAT for HBV.
    J Viral Hepat. 2018;25:718-723.
    PubMed     Text format     Abstract available


    May 2018
  92. LIU Z, Yang Q, Shi O, Ye W, et al
    The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014: an observational population based study.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12938.
    PubMed     Text format     Abstract available


  93. KRAMER JR, Puenpatom A, Erickson K, Cao Y, et al
    Real-World Effectiveness of Elbasvir/Grazoprevir in HCV-Infected Patients in the US Veterans Affairs Healthcare System.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12937.
    PubMed     Text format     Abstract available


  94. AISYAH DN, Shallcross L, Hayward A, Aldridge RW, et al
    Hepatitis C among Vulnerable Populations: A Seroprevalence Study of Homeless, People Who Inject Drugs and Prisoners in London.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12936.
    PubMed     Text format     Abstract available


  95. MARCO A, Roget M, Cervantes M, Forne M, et al
    Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and non-inmates.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12940.
    PubMed     Text format     Abstract available


  96. ZHOU Y, Zhou YH
    Is revaccination required in children who received a full primary vaccination against hepatitis B in infancy?
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12941.
    PubMed     Text format     Abstract available


  97. AGARWAL K, Ahn SH, Elkhashab M, Lau AH, et al
    Safety and Efficacy of Vesatolimod (GS-9620) in Patients with Chronic Hepatitis B Who Are Not Currently on Antiviral Treatment.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12942.
    PubMed     Text format     Abstract available


  98. JACKSON C, Gunson RN, Bradley-Stewart A, Bennet S, et al
    Epidemiology and patient characteristics of hepatitis D virus infection in the West of Scotland 2011-2016.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12939.
    PubMed     Text format     Abstract available


  99. FUJITA M, Sugiyama M, Sato Y, Nagashima K, et al
    Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan.
    J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12933.
    PubMed     Text format     Abstract available


  100. JEONG Y, Jin B, Lee HW, Park HJ, et al
    Evolution and Persistence of the Resistance-Associated Substitutions of Hepatitis C Virus after Direct-Acting Antiviral Treatment Failures.
    J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12932.
    PubMed     Text format     Abstract available


  101. AKRAM A, Islam SMR, Munshi SU, Tabassum S, et al
    Detection of Hepatitis B Virus DNA among Chronic and potential Occult HBV patients in resource-limited settings by Loop-Mediated Isothermal Amplification assay.
    J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12931.
    PubMed     Text format     Abstract available


  102. CARDOSO AC, Perez RM, de Figueiredo-Mendes C, Carvalho Leite N, et al
    Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with Controlled Attenuation Parameter (CAP).
    J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12930.
    PubMed     Text format     Abstract available


  103. DEMING R, Ford MM, Moore MS, Lim S, et al
    Evaluation of a hepatitis C clinical care coordination program's effect on treatment initiation and cure: A surveillance-based propensity score matching approach.
    J Viral Hepat. 2018 May 14. doi: 10.1111/jvh.12929.
    PubMed     Text format     Abstract available


  104. CHENG CY, Wu HH, Zou H, Lo YC, et al
    Epidemiological characteristics and associated factors of acute hepatitis A outbreak among HIV-coinfected men who have sex with men in Taiwan, June 2015-December 2016.
    J Viral Hepat. 2018 May 9. doi: 10.1111/jvh.12926.
    PubMed     Text format     Abstract available


  105. CHO YY, Lee JH, Chang Y, Nam JY, et al
    Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients.
    J Viral Hepat. 2018 May 9. doi: 10.1111/jvh.12927.
    PubMed     Text format     Abstract available


  106. ZHOU TC, Lai X, Feng MH, Tang Y, et al
    Systematic review and meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis e antigen seroconversion.
    J Viral Hepat. 2018 May 9. doi: 10.1111/jvh.12928.
    PubMed     Text format     Abstract available


  107. WANG J, Xia J, Zhang R, Yan X, et al
    A novel index using routinely clinical parameters for predicting significant liver inflammation in chronic hepatitis B.
    J Viral Hepat. 2018 May 9. doi: 10.1111/jvh.12925.
    PubMed     Text format     Abstract available


    April 2018
  108. CHI H, Japhary A, de Man RA, de Knegt RJ, et al
    Younger Age and Language Barriers are Associated with Non-adherence to Clinical Follow-up in Hepatitis B Treatment.
    J Viral Hepat. 2018 Apr 21. doi: 10.1111/jvh.12920.
    PubMed     Text format     Abstract available


  109. MARTINELLO M, Bhagani S, Gane E, Orkin C, et al
    Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12917.
    PubMed     Text format     Abstract available


  110. NFOR ON, Wu MF, Debnath T, Lee CT, et al
    Hepatitis B virus infection in Taiwan: The role of NTCP rs2296651 variant in relation to sex.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12912.
    PubMed     Text format     Abstract available


  111. BOYD A, Moh R, Maylin S, Chekaraou MA, et al
    Precore G1896A mutation is associated with reduced rates of HBsAg-seroclearance in treated HIV-hepatitis B virus co-infected patients from Western Africa.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12914.
    PubMed     Text format     Abstract available


  112. WADE AJ, McCormack A, Roder C, McDonald K, et al
    Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct acting antiviral therapy for hepatitis C.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12910.
    PubMed     Text format     Abstract available


  113. COUSIEN A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, et al
    Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs; the case of France.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12919.
    PubMed     Text format     Abstract available


  114. CAREY I, Byrne R, Childs K, Horner M, et al
    Serum NGAL can act as an early renal safety biomarker during long-term nucleos(t)ide analogue antiviral therapy in chronic hepatitis B.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12916.
    PubMed     Text format     Abstract available


  115. GENCAY M, Seffner A, Pabinger S, Gautier J, et al
    Detection of in vivo hepatitis B virus surface antigen mutations - a comparison of four routine screening assays.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12915.
    PubMed     Text format     Abstract available


  116. ANGELIDAKIS G, Hwang JP, Dandachi D, Economides MP, et al
    Universal screening for hepatitis C: a needed approach in patients with hematologic malignancies.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12913.
    PubMed     Text format     Abstract available


  117. YOO SH, Kwon JH, Nam SW, Kim HY, et al
    Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: comparison with pegylated interferon-based therapy in chronic hepatitis C patients.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12918.
    PubMed     Text format     Abstract available


  118. KOC OM, Savelkoul PHM, van Loo IHM, Peeters A, et al
    Safety and immunogenicity of HBAI20 Hepatitis B vaccine in healthy naive and non-responding adults.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12909.
    PubMed     Text format     Abstract available


  119. KUANG XJ, Jia RR, Huo RR, Yu JJ, et al
    Systematic review of risk factors of hepatocellular carcinoma after Hepatitis B Surface Antigen seroclearance.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12905.
    PubMed     Text format     Abstract available


  120. SRIDHAR S
    Use of S17 fragment containing hepatitis E virus infectious clones in cell culture experiments: the fine print does matter.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12902.
    PubMed     Text format     Abstract available


  121. TANG X, Allain JP, Wang H, Rong X, et al
    Incidence of HBV infection in young Chinese blood donors born after mandatory implementation of neonatal hepatitis B vaccination nationwide.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12901.
    PubMed     Text format     Abstract available


  122. WISLOFF T, White R, Dalgard O, Amundsen EJ, et al
    Feasibility of reaching world health organization targets for hepatitis C and the cost-effectiveness of alternative strategies.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12904.
    PubMed     Text format     Abstract available


  123. SCHNELL G, Tripathi R, Beyer J, Reisch T, et al
    Characterization of Demographics and NS5A Genetic Diversity for HCV Genotype 4-Infected Patients with or without Cirrhosis Treated with Ombitasvir/Paritaprevir/Ritonavir.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12906.
    PubMed     Text format     Abstract available


  124. MOORE MS, Bocour A, Winters A
    Dialysis Facility Screening and Testing Practices in the Era of Improved Hepatitis C Treatment.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12907.
    PubMed     Text format     Abstract available


  125. PENG Z, Hong-Bo D, Guang-Dong T, Xiao-Ke L, et al
    Serum hepatitis B surface antigen correlates with fibrosis and necroinflammation: a multicentre perspective in China.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12903.
    PubMed     Text format     Abstract available


  126. YUE X, Ge C, Zhuge S, He H, et al
    Changes and analysis of anti-HBs titres after primary immunization in 1- to 16-year-old Chinese children: A hospital-based study.
    J Viral Hepat. 2018;25:373-380.
    PubMed     Text format     Abstract available


    March 2018
  127. GODOY P, Carmona G, Manzanares S, Jane M, et al
    Trends and risk factors of hepatitis A in Catalonia after the introduction of a hepatitis A+B vaccination program.
    J Viral Hepat. 2018 Mar 31. doi: 10.1111/jvh.12900.
    PubMed     Text format     Abstract available


  128. RICCO G, Popa DC, Cavallone D, Iacob S, et al
    Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12895.
    PubMed     Text format     Abstract available


  129. HOSHINO K, Sugiyama M, Date T, Maruwaka S, et al
    Phylogenetic and phylodynamic analysis of hepatitis C virus subtype 1a in Okinawa, Japan.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12898.
    PubMed     Text format     Abstract available


  130. WANG H, Swann R, Thomas E, Innes HA, et al
    Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12897.
    PubMed     Text format     Abstract available


  131. BOYD SD, Harrington P, Komatsu TE, Naeger LK, et al
    HCV Genotype 4, 5, and 6: Distribution of Viral Subtypes and Sustained Virologic Response Rates in Clinical Trials of Approved Direct-acting Antiviral Regimens.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12896.
    PubMed     Text format     Abstract available


  132. NJOUOM R, Siffert I, Texier G, Lachenal G, et al
    The burden of Hepatitis C virus in Cameroon: Spatial epidemiology and historical perspective.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12894.
    PubMed     Text format     Abstract available


  133. GOOSSENS N, de Vito C, Mangia A, Clement S, et al
    Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12891.
    PubMed     Text format     Abstract available


  134. LI M, Gan Y, Fan C, Yuan H, et al
    Hepatitis B virus and risk of non-Hodgkin lymphoma: an updated meta-analysis of 58 studies.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12892.
    PubMed     Text format     Abstract available


  135. FEDELI U
    Increasing mortality associated with the more recent epidemic wave of Hepatitis C virus infection in Northern Italy.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12893.
    PubMed     Text format     Abstract available


  136. PAPATHEODORIDIS GV, Hatzakis A, Cholongitas E, Baptista-Leite R, et al
    Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
    J Viral Hepat. 2018;25 Suppl 1:6-17.
    PubMed     Text format     Abstract available


  137. XIANG-CHUN D, Xiao-Qing Y, Ting-Ting Y, Zhen-Hui L, et al
    Alpha-enolase regulates hepatitis B virus replication through suppression of the interferon signalling pathway.
    J Viral Hepat. 2018;25:289-295.
    PubMed     Text format     Abstract available


    February 2018
  138. DUARTE G, Williams CJ, Vasconcelos P, Nogueira P, et al
    Capacity to report on mortality attributable to chronic Hepatitis B and C infections by Member States: an exercise to monitor progress toward viral hepatitis elimination.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12882.
    PubMed     Text format     Abstract available


  139. MACLEAN CD, Berger C, Cangiano ML, Ziegelman D, et al
    Impact of Electronic Reminder Systems on Hepatitis C Screening in Primary Care.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12885.
    PubMed     Text format     Abstract available


  140. CHEN JY, Ren Y, Yan P, Belina ME, et al
    Tricyclic Antidepressant Use and the Risk of Fibrosis Progression in Hepatitis C-Infected Persons: Results from ERCHIVES.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12884.
    PubMed     Text format     Abstract available


  141. LI J, Zhang T, Gordon SC, Rupp LB, et al
    Impact of sustained virological response on risk of type 2 diabetes among hepatitis C patients in the US.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12887.
    PubMed     Text format     Abstract available


  142. YOUNOSSI ZM, Tanaka A, Eguchi Y, Henry L, et al
    Treatment of Hepatitis C Virus Leads to Economic Gains Related to Reduction in Cases of Hepatocellular Carcinoma and Decompensated Cirrhosis in Japan.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12886.
    PubMed     Text format     Abstract available


  143. OLVEIRA A, Dominguez L, Troya J, Arias A, et al
    Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals.
    J Viral Hepat. 2018 Feb 24. doi: 10.1111/jvh.12883.
    PubMed     Text format     Abstract available


  144. CACOUB P, Buggisch P, Carrion JA, S Cooke G, et al
    Direct Medical Costs Associated with the Extrahepatic Manifestations of Hepatitis C Infection in Europe.
    J Viral Hepat. 2018 Feb 24. doi: 10.1111/jvh.12881.
    PubMed     Text format     Abstract available


  145. LEE WC, Chou HS, Lee CS, Wu TH, et al
    Viral activity and outcome of hepatitis B surface antigen-positive grafts in deceased liver transplantation.
    J Viral Hepat. 2018 Feb 12. doi: 10.1111/jvh.12880.
    PubMed     Text format     Abstract available


  146. CORTESI PA, Belli LS, Facchetti R, Mazzarelli C, et al
    The optimal timing of Hepatitis C therapy in liver transplant eligible patients: cost-effectiveness analysis of new opportunities.
    J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12877.
    PubMed     Text format     Abstract available


  147. HEDENSTIERNA M, Nangarhari A, El-Sabini A, Weiland O, et al
    Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virologic response in chronic hepatitis C.
    J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12879.
    PubMed     Text format     Abstract available


  148. DELFINO CM, Cerrudo CS, Biglione M, Oubina JR, et al
    A comprehensive bioinformatic analysis of hepatitis D virus (HDV) full-length genomes.
    J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12876.
    PubMed     Text format     Abstract available


  149. ZHONG GC, Wu YL, Hao FB, Rao XW, et al
    Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population: A case-control study with propensity score analysis.
    J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12878.
    PubMed     Text format     Abstract available


  150. ZAKARIA HM, Salem TA, El-Araby HA, Salama RM, et al
    Steroid therapy in children with fulminant hepatitis A.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12873.
    PubMed     Text format     Abstract available


  151. PREDA CM, Popescu CP, Baicus C, Constantinescu I, et al
    Risk of HBV reactivation in HBV+HCV coinfected patients with compensated liver cirrhosis treated with Ombitasvir, Paritaprevir/r+Dasabuvir+Ribavirin.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12872.
    PubMed     Text format     Abstract available


  152. LUXENBURGER H, Grass F, Baermann J, Boettler T, et al
    Differential virus-specific CD8(+) T-cell epitope repertoire in hepatitis C virus genotype 1 versus 4.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12874.
    PubMed     Text format     Abstract available


  153. WALKER AJ, Peacock CJ, Pedergnana V, Irving WL, et al
    Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: A systematic review.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12871.
    PubMed     Text format     Abstract available


    January 2018
  154. ALVAREZ-OSSORIO MJ, Sarmento E Castro R, Granados R, Macias J, et al
    Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort.
    J Viral Hepat. 2018 Jan 28. doi: 10.1111/jvh.12867.
    PubMed     Text format     Abstract available


  155. GUPTA S, Rout G, Patel AH, Mahanta M, et al
    Efficacy of Generic Oral Directly Acting Agents in Patients with Hepatitis C Virus Infection.
    J Viral Hepat. 2018 Jan 28. doi: 10.1111/jvh.12870.
    PubMed     Text format     Abstract available


  156. FABER M, Willrich N, Schemmerer M, Rauh C, et al
    Hepatitis E virus seroprevalence, seroincidence and seroreversion in the German adult population.
    J Viral Hepat. 2018 Jan 28. doi: 10.1111/jvh.12868.
    PubMed     Text format     Abstract available


  157. HARRIS M, Bonnington O, Harrison G, Hickman M, et al
    Understanding hepatitis C intervention success: Qualitative findings from the HepCATT study.
    J Viral Hepat. 2018 Jan 25. doi: 10.1111/jvh.12869.
    PubMed     Text format     Abstract available


  158. YANG C, Yu W, Bi Y, Long F, et al
    Increased estradiol in hepatitis E virus infected pregnant women promote viral replication.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12865.
    PubMed     Text format     Abstract available


  159. ZHOU PP, Xu J, Dai MJ, Shi YY, et al
    The immunosuppressive effects of CD4(+) CD25(+) regulatory T cells on dendritic cells in patients with chronic hepatitis B.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12863.
    PubMed     Text format     Abstract available


  160. AYOUB HH, Al Kanaani Z, Abu-Raddad LJ
    Characterizing the temporal evolution of the hepatitis C virus epidemic in Pakistan.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12864.
    PubMed     Text format     Abstract available


  161. AISYAH DN, Shallcross L, Hully AJ, O'Brien A, et al
    Assessing Hepatitis C Spontaneous Clearance and Understanding Associated Factors: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12866.
    PubMed     Text format     Abstract available


  162. COLOMBO M, Boccaccio V
    Hepatitis C eradication with DAA and risk of liver cancer recurrence: the debate unrests.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12862.
    PubMed     Text format     Abstract available


  163. CHO H, Ahn H, Lee DH, Lee JH, et al
    Entecavir and Tenofovir Reduce Hepatitis B Virus-related Hepatocellular Carcinoma Recurrence More Effectively than Other Antivirals.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12855.
    PubMed     Text format     Abstract available


  164. LAU KC, Osiowy C, Giles E, Lusina B, et al
    Deep Sequencing Shows Low Level Oncogenic Hepatitis B Virus Variants Persisting Post-Liver Transplant Despite Potent Anti-HBV Prophylaxis.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12860.
    PubMed     Text format     Abstract available


  165. FLISIAK R, Zarebska-Michaluk D, Janczewska E, Staniaszek A, et al
    Treatment of HCV infection in Poland at the beginning of the interferon-free era - the EpiTer-2 study.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12861.
    PubMed     Text format     Abstract available


  166. YOUNG K, Haq K, MacLean S, Dudani R, et al
    Development of a recombinant murine tumor model using hepatoma cells expressing hepatitis C virus (HCV) non-structural antigens.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12856.
    PubMed     Text format     Abstract available


  167. FALADE-NWULIA O, Sulkowski MS, Merkow A, Latkin C, et al
    Understanding and addressing hepatitis C reinfection in the oral direct acting antiviral era.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12859.
    PubMed     Text format     Abstract available


  168. SCHUTZ A, Moser S, Schwanke C, Schubert R, et al
    Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk for non-adherence to direct-acting antivirals.
    J Viral Hepat. 2018 Jan 5. doi: 10.1111/jvh.12857.
    PubMed     Text format     Abstract available


    December 2017
  169. EL KASSAS M, Funk AL, Salaheldin M, Shimakawa Y, et al
    Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C infected Egyptian cohort: a comparative analysis.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12854.
    PubMed     Text format     Abstract available


  170. SULKOWSKI MS, Feld JJ, Lawitz E, Felizarta F, et al
    Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12853.
    PubMed     Text format     Abstract available


  171. HAJARIZADEH B, Grebely J, Matthews GV, Martinello M, et al
    Uptake of direct acting antiviral treatment for chronic hepatitis C in Australia.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12852.
    PubMed     Text format     Abstract available


  172. CHEN CH, Hsu YC, Lu SN, Hung CH, et al
    The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12851.
    PubMed     Text format     Abstract available


  173. KOZUKA R, Hai H, Motoyama H, Hagihara A, et al
    The Presence of Multiple NS5A RASs is Associated with the Outcome of Sofosbuvir and Ledipasvir Therapy in NS5A Inhibitor-Naive Patients with Chronic HCV Genotype 1b Infection in a Real-World Cohort.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12850.
    PubMed     Text format     Abstract available


  174. MCNAUGHTON AL, Sreenu VB, Wilkie G, Gunson R, et al
    Prevalence of mixed genotype hepatitis C virus infections in the UK as determined by genotype-specific PCR and deep sequencing.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12849.
    PubMed     Text format     Abstract available


  175. GUBAY F, Staunton R, Metzig C, Abubakar I, et al
    Assessing uncertainty in the burden of Hepatitis C Virus: comparison of estimated disease burden and treatment costs in the UK.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12847.
    PubMed     Text format     Abstract available


  176. ZENG QL, Xu GH, Wang B, Li ZQ, et al
    Prophylactic antiviral therapy for the prevention of mother-to-child transmission of hepatitis B virus can be stopped at delivery.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12848.
    PubMed     Text format     Abstract available


  177. SIMMONS R, Ireland G, Irving W, Hickman M, et al
    Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12844.
    PubMed     Text format     Abstract available


  178. RODRIGUEZ DE SANTIAGO E, Velazquez Kennedy K, Garcia Gonzalez M, Gea Rodriguez F, et al
    HCV-positive lymphoma after sustained virological response with direct-acting antiviral agents: The game is not over after HCV eradication.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12843.
    PubMed     Text format     Abstract available


  179. READ SA, Parnell G, Booth D, Douglas MW, et al
    The Antiviral Role of Zinc and Metallothioneins in Hepatitis C Infection.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12845.
    PubMed     Text format     Abstract available


  180. ERMAN A, Sathya A, Nam A, Bielecki JM, et al
    Estimating Chronic Hepatitis C Prognosis Using Transient Elastography-Based Liver Stiffness: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12846.
    PubMed     Text format     Abstract available


  181. LIU DP, Lu W, Zhang ZQ, Wang YB, et al
    Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B.
    J Viral Hepat. 2017 Dec 12. doi: 10.1111/jvh.12842.
    PubMed     Text format     Abstract available


  182. FERREIRA GLC, Marano C, De Moerlooze L, Guignard A, et al
    Incidence and prevalence of hepatitis B in patients with diabetes mellitus in the UK: a population-based cohort study using the UK Clinical Practice Research Datalink.
    J Viral Hepat. 2017 Dec 8. doi: 10.1111/jvh.12841.
    PubMed     Text format     Abstract available


  183. NAM JY, Chang Y, Cho H, Kang SH, et al
    Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
    J Viral Hepat. 2017 Dec 1. doi: 10.1111/jvh.12838.
    PubMed     Text format     Abstract available


    November 2017
  184. CHEN Y, Xie C, Zhang Y, Li Y, et al
    Knowledge regarding Hepatitis B Mother-to-child Transmission among Healthcare Workers in South China.
    J Viral Hepat. 2017 Nov 30. doi: 10.1111/jvh.12839.
    PubMed     Text format     Abstract available


  185. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison.
    J Viral Hepat. 2017 Nov 30. doi: 10.1111/jvh.12837.
    PubMed     Text format     Abstract available


  186. TAMORI A, Abiru S, Enomoto H, Kioka K, et al
    Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy.
    J Viral Hepat. 2017 Nov 30. doi: 10.1111/jvh.12840.
    PubMed     Text format     Abstract available


  187. CARLTON-SMITH C, Holmes JA, Naggie S, Lidofsky A, et al
    IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.
    J Viral Hepat. 2017 Nov 29. doi: 10.1111/jvh.12836.
    PubMed     Text format     Abstract available


  188. WANG Y, Liang X, Yang J, Wang H, et al
    Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of non-advanced liver fibrosis for chronic hepatitis B.
    J Viral Hepat. 2017 Nov 29. doi: 10.1111/jvh.12835.
    PubMed     Text format     Abstract available


  189. LIU J, Zhang S, Liu M, Wang Q, et al
    Distribution of ABO/Rh blood groups and their association with hepatitis B virus infection in 3.8 million Chinese adults: a population-based cross-sectional study.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12829.
    PubMed     Text format     Abstract available


  190. LEE HR, Cho YY, Lee GY, You DG, et al
    A direct role for hepatitis B virus X protein in inducing mitochondrial membrane permeabilization.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12831.
    PubMed     Text format     Abstract available


  191. YOUNOSSI ZM, Stepanova M, Schwarz KB, Wirth S, et al
    Quality of Life in Adolescents with Hepatitis C Treated with Sofosbuvir and Ribavirin.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12830.
    PubMed     Text format     Abstract available


  192. JENG WJ, Chen YC, Liaw YF
    Great and rapid HBsAg decline in patients with on-treatment hepatitis flare in early phase of potent antiviral therapy.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12833.
    PubMed     Text format     Abstract available


  193. TANAKA J, Akita T, Ohisa M, Sakamune K, et al
    Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12828.
    PubMed     Text format     Abstract available


  194. HU Y, Xu C, Xu B, Hu L, et al
    Safety and efficacy of telbivudine in late pregnancy to prevent mother-to-child transmission of hepatitis B virus: a multicenter prospective cohort study.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12834.
    PubMed     Text format     Abstract available


  195. HSU YC, Ho HJ, Lee TY, Huang YT, et al
    Temporal Trend and Risk Determinants of Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Entecavir or Tenofovir.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12832.
    PubMed     Text format     Abstract available


  196. KEISER O, Giudici F, Mullhaupt B, Junker C, et al
    Trends in hepatitis C-related mortality in Switzerland.
    J Viral Hepat. 2017 Nov 20. doi: 10.1111/jvh.12803.
    PubMed     Text format     Abstract available


  197. BROWN A, Hezode C, Zuckerman E, Foster GR, et al
    Efficacy and safety of 12 weeks of elbasvir +/- grazoprevir +/- ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE study.
    J Viral Hepat. 2017 Nov 20. doi: 10.1111/jvh.12801.
    PubMed     Text format     Abstract available


  198. DUCHESNE L, Lacombe K
    Innovative technologies for point-of-care testing of viral hepatitis in low-resource and decentralized settings.
    J Viral Hepat. 2017 Nov 13. doi: 10.1111/jvh.12827.
    PubMed     Text format     Abstract available


  199. BHARDWAJ N, Ragonnet-Cronin M, Murrell B, Chodavarapu K, et al
    Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.
    J Viral Hepat. 2017 Nov 7. doi: 10.1111/jvh.12825.
    PubMed     Text format     Abstract available


  200. SALMON-CERON D, Mondelli MU, Maticic M, Arends JE, et al
    The success of HCV cure: every rose has its thorn.
    J Viral Hepat. 2017 Nov 7. doi: 10.1111/jvh.12823.
    PubMed     Text format     Abstract available


  201. HIKITA H, Sato M, Sato M, Soroida Y, et al
    Disappearance of Perihepatic Lymph Node Enlargement after hepatitis C viral eradication with direct acting antivirals.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12819.
    PubMed     Text format     Abstract available


  202. CANNIZZO ES, Tincati C, Binda F, Ronzi P, et al
    Unconventional T-cells in Chronic Hepatitis B Patients on Long-Term Suppressive Therapy with Tenofovir followed by a Peg-IFN Add-On Strategy: a randomized study.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12820.
    PubMed     Text format     Abstract available


  203. DE ARAUJO NETO JM, Coelho HSM, Chindamo MC, da Motta Rezende GF, et al
    Lower levels of dehydroepiandrosterone sulfate are associated with more advanced liver fibrosis in chronic hepatitis C.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12812.
    PubMed     Text format     Abstract available


  204. MENDES LC, Ferreira PA, Miotto N, Zanaga L, et al
    Elastogram quality assessment score in Vibration Controlled Transient Elastography: Diagnostic performance compared to digital morphometric analysis of liver biopsy in chronic hepatitis C.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12822.
    PubMed     Text format     Abstract available


  205. FOSTER G
    Editorial for "Supplement on Optimal Therapy for Chronic Hepatitis B in China".
    J Viral Hepat. 2017;24 Suppl 1:3.
    PubMed     Text format    


  206. LIU J, Chen T, Zhao Y
    Telbivudine therapy for gravidas with chronic hepatitis B infection and patients at risk of renal impairment.
    J Viral Hepat. 2017;24 Suppl 1:6-11.
    PubMed     Text format     Abstract available


  207. PAN HY, Pan HY, Song WY, Zheng W, et al
    Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
    J Viral Hepat. 2017;24 Suppl 1:29-35.
    PubMed     Text format     Abstract available


  208. LUO XD, Chen XF, Zhou Y, Chen XP, et al
    Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNalpha-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    J Viral Hepat. 2017;24 Suppl 1:36-42.
    PubMed     Text format     Abstract available


  209. YI W, Li MH, Xie Y, Wu J, et al
    Prospective cohort study on the efficacy and safety of telbivudine used throughout pregnancy in blocking mother-to-child transmission of hepatitis B virus.
    J Viral Hepat. 2017;24 Suppl 1:49-56.
    PubMed     Text format     Abstract available


  210. LI SY, Li H, Xiong YL, Liu F, et al
    Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study.
    J Viral Hepat. 2017;24 Suppl 1:12-20.
    PubMed     Text format     Abstract available


  211. HUANG D, Sansas B, Jiang JH, Gong QM, et al
    Recognition of Core- and Polymerase-derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients.
    J Viral Hepat. 2017;24 Suppl 1:66-74.
    PubMed     Text format     Abstract available


  212. SHANG J, Wen Q, Wang CC, Liu K, et al
    Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: Long-term follow-up.
    J Viral Hepat. 2017;24 Suppl 1:43-48.
    PubMed     Text format     Abstract available


  213. WANG ML, Chen EQ, Zhang DM, Du LY, et al
    Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy.
    J Viral Hepat. 2017;24 Suppl 1:21-28.
    PubMed     Text format     Abstract available


  214. REN H
    The experience of management of chronic hepatitis B in China.
    J Viral Hepat. 2017;24 Suppl 1:4-5.
    PubMed     Text format     Abstract available


    October 2017
  215. CAMPANA B, Calabrese D, Matter MS, Terracciano LM, et al
    In vivo analysis at the cellular level reveals similar steatosis induction in both HCV genotype 1 and 3 infections.
    J Viral Hepat. 2017 Oct 31. doi: 10.1111/jvh.12816.
    PubMed     Text format     Abstract available


  216. LIANG X, Xie Q, Tan D, Ning Q, et al
    Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy: a 2-year prospective study.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12814.
    PubMed     Text format     Abstract available


  217. MA N, Zhang X, Yang L, Zhou J, et al
    Role of Functional IFNL4, IFNLR1, IFNA, IFNAR2 Polymorphisms in Hepatitis B virus-related liver disease in Han Chinese population.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12817.
    PubMed     Text format     Abstract available


  218. CHOI HY, Kim Y, Cho H, Kim BH, et al
    Risk of diabetes in viral hepatitis B or C patients compared to that in non-infected individuals in Korea, 2002-2013: A population-based cohort study.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12815.
    PubMed     Text format     Abstract available


  219. MARCELLIN F, Morlat P, Wittkop L, Salmon-Ceron D, et al
    Impaired patient-reported outcomes persist in HIV-HCV co-infected patients and in cirrhotic patients despite HCV clearance.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12811.
    PubMed     Text format     Abstract available


  220. OW MM, Hegazy D, Warshow UM, Cramp ME, et al
    Enhanced natural killer cell activity is found in exposed uninfected recipients of hepatitis C-contaminated blood.
    J Viral Hepat. 2017 Oct 24. doi: 10.1111/jvh.12810.
    PubMed     Text format     Abstract available


  221. SALUDES V, Folch C, Morales-Carmona A, Ferrer L, et al
    Community-based screening of hepatitis C with a one-step RNA detection algorithm from dried-blood spots: analysis of key populations in Barcelona, Spain.
    J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12809.
    PubMed     Text format     Abstract available


  222. YOUNOSSI ZM, Chan HLY, Dan YY, Lee MH, et al
    Impact of Ledipasvir/Sofosbuvir on the Work Productivity of Genotype 1 Chronic Hepatitis C Patients in Asia.
    J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12808.
    PubMed     Text format     Abstract available


  223. NAYLOR PH, Mutchnick MG
    Immunotherapy for Hepatitis B in the Direct Acting Anti-viral Era: Reevaluating the Thymosin alpha1 Efficacy Trials in Light of a Combination Therapy Approach.
    J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12807.
    PubMed     Text format     Abstract available


  224. WEN X, Su H, Wang Y, Pu Z, et al
    Prevalence and natural course of occult hepatitis B virus infection in residents of two communities of Wuwei City, Gansu Province, China.
    J Viral Hepat. 2017 Oct 15. doi: 10.1111/jvh.12805.
    PubMed     Text format     Abstract available


  225. WONG NS, Lee CK, Ng SC, Wong HK, et al
    Prevalence of hepatitis C infection and its associated factors in healthy adults without identifiable route of transmission.
    J Viral Hepat. 2017 Oct 15. doi: 10.1111/jvh.12804.
    PubMed     Text format     Abstract available


  226. MARRONE A, Capoluongo N, D'Amore C, Pisaturo M, et al
    Eighteen-month-lamivudine-prophylaxis on preventing occult hepatitis b virus (hbv) infection reactivation in patients with hematologic malignancies receiving immunosuppression therapy.
    J Viral Hepat. 2017 Oct 13. doi: 10.1111/jvh.12802.
    PubMed     Text format     Abstract available


  227. CAMUS G, Han B, Asselah T, Hsieh D, et al
    Resistance Characterization of Ledipasvir and Velpatasvir in Hepatitis C Virus Genotype 4.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12795.
    PubMed     Text format     Abstract available


  228. TANG L, Parker A, Flores Y, Dellario M, et al
    Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: highly effective in a predominantly black male patient population.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12796.
    PubMed     Text format     Abstract available


  229. NORDMANN S, Vilotitch A, Roux P, Esterle L, et al
    Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus co-infected patients (ANRS CO13-HEPAVIH).
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12797.
    PubMed     Text format     Abstract available


  230. SRIDHAR S, Chan JFW, Yap DYH, Teng JLL, et al
    Genotype 4 hepatitis E virus is a cause of chronic hepatitis in renal transplant recipients in Hong Kong.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12799.
    PubMed     Text format     Abstract available


  231. WEIL C, Mehta D, Koren G, Pinsky B, et al
    Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12800.
    PubMed     Text format     Abstract available


  232. CHEN DS, Hamoudi W, Mustapha B, Layden J, et al
    Strategies to manage hepatitis C virus infection disease burden-Volume 4.
    J Viral Hepat. 2017;24 Suppl 2:44-63.
    PubMed     Text format     Abstract available


  233. MAAROUFI A, Vince A, Himatt SM, Mohamed R, et al
    Historical epidemiology of hepatitis C virus in select countries-volume 4.
    J Viral Hepat. 2017;24 Suppl 2:8-24.
    PubMed     Text format     Abstract available


  234. DORE GJ, Hatzakis A, Negro F, Waked I, et al
    Estimating HCV disease burden-volume 4 (editorial).
    J Viral Hepat. 2017;24 Suppl 2:4-7.
    PubMed     Text format     Abstract available


  235. CHAN HLY, Chen CJ, Omede O, Al Qamish J, et al
    The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4.
    J Viral Hepat. 2017;24 Suppl 2:25-43.
    PubMed     Text format     Abstract available


    August 2017
  236. SERPER M, Forde KA, Kaplan DE
    Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: data from a national US cohort.
    J Viral Hepat. 2017 Aug 28. doi: 10.1111/jvh.12784.
    PubMed     Text format     Abstract available


  237. ZHENG H, Cui FQ, Wang FZ, Huang LF, et al
    The epidemiology of hepatitis B virus infection in women of reproductive age in highly endemic areas in China.
    J Viral Hepat. 2017 Aug 23. doi: 10.1111/jvh.12757.
    PubMed     Text format     Abstract available


  238. SHAFRAN SD, Shaw D, Charafeddine M, Agarwal K, et al
    Efficacy and Safety Results of Patients with HCV Genotype 2 or 3 Infection Treated with Ombitasvir/Paritaprevir/ritonavir and Sofosbuvir with or without Ribavirin (QUARTZ II-III).
    J Viral Hepat. 2017 Aug 20. doi: 10.1111/jvh.12782.
    PubMed     Text format     Abstract available


  239. KITRINOS KM, Corsa AC, Worth A, Hedskog C, et al
    Nonstructural Protein 5A (NS5A) Resistance Profile in Patients with Chronic Hepatitis C Treated with Ledipasvir-Containing Regimens Without Sofosbuvir.
    J Viral Hepat. 2017 Aug 20. doi: 10.1111/jvh.12783.
    PubMed     Text format     Abstract available


  240. KRAMER JR, El-Serag HB, Taylor TJ, White DL, et al
    Hepatitis C virus-related complications are increasing in women veterans: A national cohort study.
    J Viral Hepat. 2017 Aug 16. doi: 10.1111/jvh.12728.
    PubMed     Text format     Abstract available


  241. BARONE M, Iannone A, Shahini E, Ippolito AM, et al
    A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: the ITAL-C network study.
    J Viral Hepat. 2017 Aug 8. doi: 10.1111/jvh.12765.
    PubMed     Text format     Abstract available


  242. MERCHANTE N, Aldamiz-Echevarria T, Garcia-Alvarez M, Rivero-Juarez A, et al
    Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients.
    J Viral Hepat. 2017 Aug 7. doi: 10.1111/jvh.12769.
    PubMed     Text format     Abstract available


  243. VON FELDEN J, Scheurich C, Yamamura J, Brainard DM, et al
    Successful treatment of chronic hepatitis C with ground ledipasvir / sofosbuvir in a patient with Crohn's disease and short bowel syndrome.
    J Viral Hepat. 2017 Aug 7. doi: 10.1111/jvh.12768.
    PubMed     Text format     Abstract available


  244. FOURNIER C, Hoffmann TW, Morel V, Descamps V, et al
    Claudin-1, miR-122 and Apolipoprotein E transduction improves the permissivity of SNU-182, SNU-398 and SNU-449 Hepatoma cells to Hepatitis C Virus.
    J Viral Hepat. 2017 Aug 3. doi: 10.1111/jvh.12767.
    PubMed     Text format     Abstract available


  245. HUI RW, Seto WK, Cheung KS, Mak LY, et al
    Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case control study.
    J Viral Hepat. 2017 Aug 3. doi: 10.1111/jvh.12766.
    PubMed     Text format     Abstract available


    July 2017
  246. HALLAGER S, Ladelund S, Kjaer MS, Madsen LG, et al
    Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: a nationwide cohort study.
    J Viral Hepat. 2017 Jul 27. doi: 10.1111/jvh.12764.
    PubMed     Text format     Abstract available


  247. JACKA B, Bray B, Applegate TL, Marshall BD, et al
    Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.
    J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12758.
    PubMed     Text format     Abstract available


  248. SOLOMON SS, Sulkowski MS, Amrose P, Srikrishnan AK, et al
    Directly Observed Therapy of Sofosbuvir/Ribavirin +/- Peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT).
    J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12761.
    PubMed     Text format     Abstract available


  249. CHAKRABARTY G, Bruce M, Horner M, Wang B, et al
    Can Quantitative Hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?
    J Viral Hepat. 2017 Jul 14. doi: 10.1111/jvh.12756.
    PubMed     Text format     Abstract available


  250. CALVARUSO V, Ferraro D, Licata A, Bavetta MG, et al
    HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct acting antivirals.
    J Viral Hepat. 2017 Jul 13. doi: 10.1111/jvh.12754.
    PubMed     Text format     Abstract available


  251. GARDNER SD, Kim J, Baptiste-Brown S, Lopez V, et al
    GSK2878175, a pan-genotypic non-nucleoside NS5B polymerase inhibitor, in healthy and treatment-naive chronic hepatitis C subjects.
    J Viral Hepat. 2017 Jul 10. doi: 10.1111/jvh.12753.
    PubMed     Text format     Abstract available


  252. AL-QAHTANI AA, Al-Anazi MR, Nazir N, Wani K, et al
    Association of Single Nucleotide Polymorphisms in MicroRNAs with Susceptibility to Hepatitis B Virus Infection and HBV-related Liver Complications: A Study in a Saudi Arabian Population.
    J Viral Hepat. 2017 Jul 7. doi: 10.1111/jvh.12749.
    PubMed     Text format     Abstract available


  253. SALAZAR-VIZCAYA L, Kouyos RD, Fehr J, Braun D, et al
    On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: a mathematical modelling study.
    J Viral Hepat. 2017 Jul 7. doi: 10.1111/jvh.12752.
    PubMed     Text format     Abstract available


  254. LI Q, Lu C, Li W, Huang Y, et al
    The gamma-glutamyl transpeptidase to albumin ratio predicts significant fibrosis and cirrhosis in chronic hepatitis B patients.
    J Viral Hepat. 2017 Jul 7. doi: 10.1111/jvh.12751.
    PubMed     Text format     Abstract available


    June 2017
  255. BENOVA L, Awad SF, Abu-Raddad LJ
    Estimate of vertical transmission of Hepatitis C virus in Pakistan in 2007 and 2012 birth cohorts.
    J Viral Hepat. 2017 Jun 29. doi: 10.1111/jvh.12748.
    PubMed     Text format     Abstract available


  256. LI Y, Li Y, Zhang L, Li W, et al
    Hepatitis C virus infection and risk of multiple myeloma: evidence from a meta-analysis based on 17 case-control studies.
    J Viral Hepat. 2017 Jun 28. doi: 10.1111/jvh.12742.
    PubMed     Text format     Abstract available


  257. SIDDIQUI ZI, Farooqui SR, Azam SA, Afroz M, et al
    A comparative study of hepatitis B virus X protein mutants K130M, V131I and KV130/131MI to investigate their roles in fibrosis, cirrhosis and hepatocellular carcinoma.
    J Viral Hepat. 2017 Jun 27. doi: 10.1111/jvh.12747.
    PubMed     Text format     Abstract available


  258. TENG W, Hsieh YC, Lui KW, Chen WT, et al
    Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization.
    J Viral Hepat. 2017 Jun 22. doi: 10.1111/jvh.12745.
    PubMed     Text format     Abstract available


  259. SCHIAVINATO A, Zanetto A, Pantano G, Tosato F, et al
    Polyclonal and monoclonal B-lymphocytes response in HCV patients treated with direct-acting antiviral agents.
    J Viral Hepat. 2017 Jun 22. doi: 10.1111/jvh.12746.
    PubMed     Text format     Abstract available


  260. DE LA TORRE AN, Castaneda I, Ahmad M, Ekholy N, et al
    Audio Computer Assisted Survey Interview and Patient Navigation to Increase Chronic Viral Hepatitis Diagnosis and Linkage to Care in Urban Health Clinics.
    J Viral Hepat. 2017 Jun 21. doi: 10.1111/jvh.12744.
    PubMed     Text format     Abstract available


  261. DIRKS M, Pflugrad H, Weissenborn K
    Response to letter to the editor: Persistent neuropsychiatric impairment in HCV patients - or educational mismatch?!
    J Viral Hepat. 2017 Jun 21. doi: 10.1111/jvh.12740.
    PubMed     Text format     Abstract available


  262. YANG R, Gui X, Xiong Y, Gao S, et al
    Long-term Follow-up of Patients Triply Infected with HIV and Hepatitis B and C Viruses in a Comprehensive Hospital in Central China.
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12739.
    PubMed     Text format     Abstract available


  263. GADE A
    Persistent neuropsychiatric impairment in HCV patients - or educational mismatch?!
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12743.
    PubMed     Text format     Abstract available


  264. KAWAGISHI N, Suda G, Onozawa M, Kimura M, et al
    Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12737.
    PubMed     Text format     Abstract available


  265. STELMA F, van der Ree MH, Jansen L, Peters MW, et al
    HBsAg loss after peginterferon and nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12738.
    PubMed     Text format     Abstract available


  266. JOHNSON K, Green PK, Ioannou GN
    Implications of HCV RNA level at week 4 of direct antiviral treatments for Hepatitis C.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12731.
    PubMed     Text format     Abstract available


  267. WONG RJ, Nguyen MT, Trinh HN, Chan C, et al
    Hepatitis B Surface Antigen Loss and Sustained Viral Suppression in Asian Chronic Hepatitis B Patients: A Community-Based Real World Study.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12736.
    PubMed     Text format     Abstract available


  268. KIM HS, Rotundo L, Yang JD, Kim D, et al
    Racial/ethnic disparities in the prevalence and awareness of Hepatitis B virus infection and immunity in the United States.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12735.
    PubMed     Text format     Abstract available


  269. EL SHERIF O, Afhdal N, Curry M
    No one size fits all - shortening duration of therapy with direct acting antivirals for Hepatitis C genotype 1 infection.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12734.
    PubMed     Text format     Abstract available


  270. NING L, Lin W, Hu X, Rong F, et al
    Prevalence of chronic kidney disease in patients with chronic hepatitis B: A cross-sectional survey.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12733.
    PubMed     Text format     Abstract available


  271. LOK AS, Ganova-Raeva L, Cloonan Y, Punkova L, et al
    Prevalence of Hepatitis B Antiviral Drug Resistance Variants in North American Patients with Chronic Hepatitis B Not Receiving Antiviral Treatment.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12732.
    PubMed     Text format     Abstract available


  272. SHARMA S, Kumar A, Kar P, Agarwal S, et al
    Risk factors for vertical transmssion of hepatitis E virus infection.
    J Viral Hepat. 2017 Jun 1. doi: 10.1111/jvh.12730.
    PubMed     Text format     Abstract available


  273. HAN GR, Jiang HX, Wang CM, Ding Y, et al
    Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy.
    J Viral Hepat. 2017;24:514-521.
    PubMed     Text format     Abstract available


    May 2017
  274. BROUWER WP, van der Meer AJ, Boonstra A, Plompen EPC, et al
    Prediction of long-term clinical outcome in a diverse chronic hepatitis b population: role of the PAGE-B score.
    J Viral Hepat. 2017 May 24. doi: 10.1111/jvh.12727.
    PubMed     Text format     Abstract available


  275. FITCH DN, Dharod A, Campos CL, Nunez M, et al
    Use of Electronic Health Record Clinical Decision Support Tool for HCV Birth Cohort Screening.
    J Viral Hepat. 2017 May 24. doi: 10.1111/jvh.12729.
    PubMed     Text format     Abstract available


  276. ROB B, Moreno C, Van Vlierberghe H, Bourgeois S, et al
    The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without Pegylated Interferon: A Belgian experience.
    J Viral Hepat. 2017 May 15. doi: 10.1111/jvh.12726.
    PubMed     Text format     Abstract available


  277. OSIBOGUN O, Ogunmoroti O, Michos ED, Spatz ES, et al
    HIV/HCV Co-infection and the risk of Cardiovascular Disease: A Meta-analysis.
    J Viral Hepat. 2017 May 14. doi: 10.1111/jvh.12725.
    PubMed     Text format     Abstract available


  278. MCLEOD A, Cullen BL, Hutchinson SJ, Roy KM, et al
    Limited Impact of Awareness-Raising Campaigns on Hepatitis C Testing Practices among General Practitioners.
    J Viral Hepat. 2017 May 14. doi: 10.1111/jvh.12724.
    PubMed     Text format     Abstract available


  279. KIM GA, Han S, Kim HD, An J, et al
    Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis B vs Chronic Hepatitis C after Achievement of Virologic Response.
    J Viral Hepat. 2017 May 12. doi: 10.1111/jvh.12723.
    PubMed     Text format     Abstract available


  280. WEDEMEYER H, Craxi A, Zuckerman E, Dieterich D, et al
    Real-World Effectiveness of Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir +/- Ribavirin in Patients with HCV Genotype 1 or 4 Infection: a Meta-Analysis.
    J Viral Hepat. 2017 May 8. doi: 10.1111/jvh.12722.
    PubMed     Text format     Abstract available


  281. SHAWA IT, Felmlee DJ, Hegazy D, Sheridan DA, et al
    Exploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug users.
    J Viral Hepat. 2017 May 5. doi: 10.1111/jvh.12720.
    PubMed     Text format     Abstract available


  282. HLAING NKT, Mitrani RA, Aung ST, Phyo WW, et al
    Safety and Efficacy of Sofosbuvir-Based DAA Regimens for Hepatitis C Virus Genotypes 1 - 4 and 6 in Myanmar: Real-world experience.
    J Viral Hepat. 2017 May 5. doi: 10.1111/jvh.12721.
    PubMed     Text format     Abstract available


  283. GANE E, Nahass R, Luketic V, Asante-Appiah E, et al
    Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naive, non-cirrhotic HCV genotype 3-infected patients.
    J Viral Hepat. 2017 May 4. doi: 10.1111/jvh.12719.
    PubMed     Text format     Abstract available


    April 2017
  284. STEININGER K, Boyd A, Dupke S, Krznaric I, et al
    HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
    J Viral Hepat. 2017 Apr 25. doi: 10.1111/jvh.12707.
    PubMed     Text format     Abstract available


  285. LAARIBI AB, Bortolotti D, Hannachi N, Mehri A, et al
    Increased levels of soluble HLA-G molecules in Tunisian patients with chronic hepatitis B infection.
    J Viral Hepat. 2017 Apr 21. doi: 10.1111/jvh.12718.
    PubMed     Text format     Abstract available


  286. CAI YJ, Dong JJ, Wang XD, Huang SS, et al
    A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12715.
    PubMed     Text format     Abstract available


  287. PAPASAVVAS E, Azzoni L, Yin X, Liu Q, et al
    HCV viremia associates with NK cell activation and dysfunction in anti retroviral HIV/HCV co-infected subjects.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12714.
    PubMed     Text format     Abstract available


  288. DE GROEN RA, Groothuismink ZMA, van Oord G, Kootstra NA, et al
    NK cells in self-limited HCV infection exhibit a more extensively differentiated, but not memory-like, repertoire.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12716.
    PubMed     Text format     Abstract available


  289. MGAIETH S, Kemp W, Gow P, Fink M, et al
    Impact of viral hepatitis etiology on survival outcomes in hepatocellular carcinoma: a large multi-center cohort study.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12717.
    PubMed     Text format     Abstract available


  290. HUANG CE, Yang YH, Chen YY, Chang JJ, et al
    The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma.
    J Viral Hepat. 2017 Apr 4. doi: 10.1111/jvh.12713.
    PubMed     Text format     Abstract available


    March 2017
  291. VUKOTIC R, Conti F, Fagiuoli S, Morelli MC, et al
    Long-term outcomes of DAAs in post-transplant advanced HCV recurrence and fibrosing cholestatic hepatitis.
    J Viral Hepat. 2017 Mar 28. doi: 10.1111/jvh.12712.
    PubMed     Text format     Abstract available


  292. BOGLIONE L, Mornese Pinna S, De Nicolo A, Cusato J, et al
    Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study.
    J Viral Hepat. 2017 Mar 26. doi: 10.1111/jvh.12711.
    PubMed     Text format     Abstract available


  293. XU JH, Wang S, Xu ZN, Yu YY, et al
    Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: results at week 144.
    J Viral Hepat. 2017 Mar 26. doi: 10.1111/jvh.12710.
    PubMed     Text format     Abstract available


  294. SU H, Shao Z, Pu Z, Wang Y, et al
    Overt and occult hepatitis B virus infection among community children in Northwest China.
    J Viral Hepat. 2017 Mar 25. doi: 10.1111/jvh.12709.
    PubMed     Text format     Abstract available


  295. WELZEL TM, Hinrichsen H, Sarrazin C, Buggisch P, et al
    Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.
    J Viral Hepat. 2017 Mar 25. doi: 10.1111/jvh.12708.
    PubMed     Text format     Abstract available


    January 2017
  296. VUKOTIC R, Di Donato R, Conti F, Scuteri A, et al
    Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort.
    J Viral Hepat. 2017;24:13-16.
    PubMed     Text format     Abstract available


  297. LI X, Gou C, Yao L, Lei Z, et al
    Patients with HBV-related acute-on-chronic liver failure have increased concentrations of extracellular histones aggravating cellular damage and systemic inflammation.
    J Viral Hepat. 2017;24:59-67.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: